RayzeBio, Inc.
(NASDAQ GM: RYZB)
Rigrodsky Law, P.A. is investigating RayzeBio, Inc. (“RayzeBio”) regarding possible breaches of fiduciary duties and other violations of law related to RayzeBio’s agreement to be acquired by Bristol-Myers Squibb Company. Under the terms of the agreement, RayzeBio shareholders will receive $62.50 per share in cash.